Apomorphine (Uprima)
Apomorphine
Abbott Laboratories S.A. (Pty) Ltd
Registration
- Applicant
- Abbott Laboratories S.A. (Pty) Ltd
- Registrations
- 2
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Uprima 2 MG EACH TABLET CONTAINS APOMORPHINE HYDROCHLORIDE (HEMIHYDRATE) EQUIVALENT TO APOMORPHINE 2,0 mg | 2 mg | 35020435/34/0204 | Registered | Not determined | None |
| Uprima 3 MG EACH TABLET CONTAINS APOMORPHINE HYDROCHLORIDE (HEMIHYDRATE) EQUIVALENT TO APOMORPHINE 3,0 mg | 3 mg | 35020535/34/0205 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Apomorphine
- when indicated for the treatment of erectile dysfunction.
Consolidated Schedules 06 July 2026, line 5325
S2: Apomorphine
- except when indicated for the treatment of erectile dysfunction.
Consolidated Schedules 06 July 2026, line 1604
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(6AR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol
Drag to rotate. Structure from PubChem CID 6005.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.